Patients were randomly assigned to receive oral paricalcitol or placebo. Dosing took place three times weekly, starting at 2 µ g or 4 µ g per dose (two trials) or once daily, starting at 1 µ g ...

Paricalcitol 2mcg/mL, 5mcg/mL; soln for IV inj; contains alcohol. Give as IV bolus inj during dialysis. Initially 0.04–0.1mcg/kg (2.8–7mcg) no more often than every other day; may increase in ...

A decision analysis model focusing on hospitalisation, survival rates and utilities for paricalcitol and calcitriol was used (Figure 1). Costs included yearly cost for medications and the costs ...

The vitamin D receptor activator (VDRA) paricalcitol produced a similar reduction in serum PTH levels to that achieved by cinacalcet in patients with stages 3–4 CKD, but with no notable increase ...